Filing Flows › NewAmsterdam Pharma Co N.V. (NAMS) › Q1 2026
NewAmsterdam Pharma Co N.V. (NAMS) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
NewAmsterdam Pharma Co N.V. (NAMS) reported revenue of $3.0M for the first quarter 2026 (Q1 2026), +2% from a year earlier and up 95-fold from the quarter before.
NewAmsterdam Pharma Co N.V., Q1 2026: revenue $3.0M (+2% year over year), net loss $48.4M, operating cash flow −$30.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.0M | 95× | +2% |
| Operating profit | −$58.4M | — | — |
| Net earnings | −$48.4M | — | — |
| Operating cash flow | −$30.6M | — | — |
What changed
Revenue was $3.0M in Q1 2026, up 2% year over year and up 9400% from the previous quarter.
Operating costs exceeded revenue by $58.4M, an operating margin of -1921.7%. Total costs fell 15% while revenue rose 2%. The quarter ended with a net loss of $48.4M, narrower than the previous quarter's $74.9M loss. Non-operating items added $10.0M, -21% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$30.6M. Non-cash charges added back $62K of depreciation and amortization and $18.0M of share-based compensation. Capital expenditures of $38K exceeded it, leaving free cash flow of −$30.6M.
Questions
What was NewAmsterdam Pharma Co N.V.'s revenue in the first quarter 2026?
NewAmsterdam Pharma Co N.V.